92 related articles for article (PubMed ID: 15072768)
1. Lethal mutagens: broad-spectrum antivirals with limited potential for development of resistance?
Freistadt MS; Meades GD; Cameron CE
Drug Resist Updat; 2004 Feb; 7(1):19-24. PubMed ID: 15072768
[TBL] [Abstract][Full Text] [Related]
2. Ribavirin and lethal mutagenesis of poliovirus: molecular mechanisms, resistance and biological implications.
Vignuzzi M; Stone JK; Andino R
Virus Res; 2005 Feb; 107(2):173-81. PubMed ID: 15649563
[TBL] [Abstract][Full Text] [Related]
3. Antiviral resistance and impact on viral replication capacity: evolution of viruses under antiviral pressure occurs in three phases.
Nijhuis M; van Maarseveen NM; Boucher CA
Handb Exp Pharmacol; 2009; (189):299-320. PubMed ID: 19048205
[TBL] [Abstract][Full Text] [Related]
4. [Ribavirin--pharmacological features, antiviral effects against hepatitis C virus (HCV) and other viruses and side effects during treatment].
Wawrzynowicz-Syczewska M
Przegl Epidemiol; 2002; 56 Suppl 5():35-40. PubMed ID: 15553070
[TBL] [Abstract][Full Text] [Related]
5. Ribavirin: is it a mutagen for hepatitis C virus?
Perelson AS; Layden TJ
Gastroenterology; 2007 May; 132(5):2050-2. PubMed ID: 17484896
[No Abstract] [Full Text] [Related]
6. Mode of selection and experimental evolution of antiviral drugs resistance in vesicular stomatitis virus.
Cuevas JM; Sanjuán R; Moya A; Elena SF
Infect Genet Evol; 2005 Jan; 5(1):55-65. PubMed ID: 15567139
[TBL] [Abstract][Full Text] [Related]
7. Resistance mechanisms in HCV: from evolution to intervention.
Kim AY; Timm J
Expert Rev Anti Infect Ther; 2008 Aug; 6(4):463-78. PubMed ID: 18662114
[TBL] [Abstract][Full Text] [Related]
8. Analysis of ribavirin mutagenicity in human hepatitis C virus infection.
Chevaliez S; Brillet R; Lázaro E; Hézode C; Pawlotsky JM
J Virol; 2007 Jul; 81(14):7732-41. PubMed ID: 17494069
[TBL] [Abstract][Full Text] [Related]
9. The hepatitis C virus life cycle as a target for new antiviral therapies.
Pawlotsky JM; Chevaliez S; McHutchison JG
Gastroenterology; 2007 May; 132(5):1979-98. PubMed ID: 17484890
[TBL] [Abstract][Full Text] [Related]
10. Resistance of high fitness hepatitis C virus to lethal mutagenesis.
Gallego I; Gregori J; Soria ME; García-Crespo C; García-Álvarez M; Gómez-González A; Valiergue R; Gómez J; Esteban JI; Quer J; Domingo E; Perales C
Virology; 2018 Oct; 523():100-109. PubMed ID: 30107298
[TBL] [Abstract][Full Text] [Related]
11. Interferon-alpha and ribavirin resistance of Huh7 cells transfected with HCV subgenomic replicon.
Aus dem Siepen M; Oniangue-Ndza C; Wiese M; Ross S; Roggendorf M; Viazov S
Virus Res; 2007 Apr; 125(1):109-13. PubMed ID: 17254660
[TBL] [Abstract][Full Text] [Related]
12. Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection.
Horsmans Y; Berg T; Desager JP; Mueller T; Schott E; Fletcher SP; Steffy KR; Bauman LA; Kerr BM; Averett DR
Hepatology; 2005 Sep; 42(3):724-31. PubMed ID: 16116638
[TBL] [Abstract][Full Text] [Related]
13. The anti-yellow fever virus activity of ribavirin is independent of error-prone replication.
Leyssen P; De Clercq E; Neyts J
Mol Pharmacol; 2006 Apr; 69(4):1461-7. PubMed ID: 16421290
[TBL] [Abstract][Full Text] [Related]
14. Beneficial effects of population bottlenecks in an RNA virus evolving at increased error rate.
Cases-González C; Arribas M; Domingo E; Lázaro E
J Mol Biol; 2008 Dec; 384(5):1120-9. PubMed ID: 18951905
[TBL] [Abstract][Full Text] [Related]
15. RNA virus error catastrophe: direct molecular test by using ribavirin.
Crotty S; Cameron CE; Andino R
Proc Natl Acad Sci U S A; 2001 Jun; 98(12):6895-900. PubMed ID: 11371613
[TBL] [Abstract][Full Text] [Related]
16. Quasispecies, error catastrophe, and the antiviral activity of ribavirin.
Graci JD; Cameron CE
Virology; 2002 Jul; 298(2):175-80. PubMed ID: 12127780
[TBL] [Abstract][Full Text] [Related]
17. Combination of a hepatitis C virus NS3-NS4A protease inhibitor and alpha interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicon cells.
Lin K; Kwong AD; Lin C
Antimicrob Agents Chemother; 2004 Dec; 48(12):4784-92. PubMed ID: 15561857
[TBL] [Abstract][Full Text] [Related]
18. New drugs for hepatitis C virus.
Pockros PJ
Expert Rev Gastroenterol Hepatol; 2007 Oct; 1(1):145-54. PubMed ID: 19072442
[TBL] [Abstract][Full Text] [Related]
19. Serine protease inhibitors as anti-hepatitis C virus agents.
Reiser M; Timm J
Expert Rev Anti Infect Ther; 2009 Jun; 7(5):537-47. PubMed ID: 19485794
[TBL] [Abstract][Full Text] [Related]
20. Ribavirin posology, observance, and sustained virologic response.
Couzigou P; Foucher J; Castera L; De Ledinghen V
Clin Gastroenterol Hepatol; 2008 Mar; 6(3):367. PubMed ID: 18063421
[No Abstract] [Full Text] [Related]
[Next] [New Search]
